Ayala Pharmaceuticals Inc (STU:FAD)
€ 0.01 -0.04 (-80%) Market Cap: 788,000.00 Enterprise Value: 3.88 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

Biosight Ltd and Advaxis Inc to Discuss Proposed Transaction Call Transcript

Jul 06, 2021 / 12:30PM GMT
Operator

Greetings, and welcome to the Advaxis and Biosight merger announcement. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Mr. Tim McCarthy with LifeSci Advisors. Thank you. You may begin.

Timothy McCarthy
LifeSci Advisors, LLC - MD & Relationship Manager

Thank you, Melissa. Good morning. Joining me on today's call are Ken Berlin, President and CEO and Interim Chief Financial Officer of Advaxis; Andres Gutierrez; EVP and Chief Medical Officer of Advaxis; Dr. Ruth Ben Yakar, CEO of Biosight; Roy Golan, EVP and Chief Financial Officer of Biosight; and Darrel Cohen, Chief Medical Officer of Biosight. A replay of today's call will be available on the Investors section of the Advaxis' website and the [new site] for 90 days.

Before proceeding, we'd like to remind participants that during the course of this call, representatives of Advaxis or Biosight may provide information that contains forward-looking statements. These statements are based on assumptions that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot